Seattle, WA, August 24, 2015 (Newswire.com) - RareCyte, a life science company that provides globally deployable solutions to characterize, isolate and analyze rare cells from patients, has named Michael A. Nemzek as its President.
“RareCyte is on an upward trajectory and enhancing our leadership team is critical to our success,” said RareCyte CEO Ron Seubert. “We are delighted to have Mike join our company and excited to have him leading our key growth initiatives.”
Nemzek comes most recently from Affymetrix, where he served as Vice President of Strategic Marketing. While there, he was responsible for developing and managing strategy, in-licensing and product life cycle management. His efforts at Affymetrix contributed to dramatic growth in the company’s genotyping business. Nemzek’s leadership expertise extends throughout the new product introduction process and growing commercial operations. Prior to Affymetrix, Nemzek held various executive leadership roles successfully growing several early stage companies.
“It is thrilling to join RareCyte in its work to bring customers an innovative technology platform that enables the analysis of rare circulating cells across the spectrum of disease with the capability to deliver unprecedented insight into human health” said Nemzek. “I couldn't be more enthusiastic to build upon what Ron and his team have created to further drive success as the company moves to broader commercialization.”
RareCyte believes that rare cells hold many of the answers to difficult human health questions. Their AccuCyte™ platform allows for the precise characterization of cancer cells, fetal cells and organisms in blood and other biological samples at the individual rare cell level.
(Products mentioned in this release are for research use only. Not for use in diagnostic procedures.)
RareCyte is a Seattle-based life science research company focused on characterizing and isolating rare cells from human samples. RareCyte is dedicated to bringing its innovative products to Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer, infectious disease and reproductive health. For more information about RareCyte, visit rarecyte.com.